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for analyzing data and p-values Results: Thirty-eight patients were included and 
the common infection types are pneumonia (N= 13); UTI (N= 12); cellutitis (N= 9) and 
sepsis (N= 9). The common pathogens are Staphylococci (19%) and Pseudomona species 
(21%). Twenty-one percent of cases used UFO® as empirical or first-line therapy. 
Combination therapies with cephalosporins (26%) or penicillins (24%) were more 
frequent. In cephalosporins combinination therapy, the most combined antibiot-
ics are 3th cephalosporins (75%). In penicillins combinination therapy, the most 
combined antibiotics is oxacillin (40%). Mean treatment duration of UFO is 9.4 days. 
There were 71% cases using common dose of UFO®, 8-12 g/day, and 29% using 
low dose, 4-6 g/day. In patients with UFO®, 74% had negative outcomes (defined 
as patient died, hypernatremia events and changed to other antibiotics) and 26% 
had positive outcomes (defined as patients discharged, disease improved and no 
recurrent fever). Most patients developed hypernatremia (serum sodium level > 145 
mEq/L) after using UFO® for 4-6 days; patients with creatinine clearance above 50 
ml/min did not develop hypernatremia. ConClusions: The serum sodium level 
didn’t increase significantly until day 4-6 after starting UFO®. For patients with 
higher baseline serum sodium level and renal dysfunction, sodium level should be 
monitored closely while using UFO®. Using UFO® as adjunct for first line or empiric 
treatments is lack of evidence. Further antibiotic prescribing regulations should be 
implemented concerning prescribing UFO®.
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objeCtives: Drugs retail outlets constitute a major source of malaria treatment 
in developing countries requiring regular and accurate information for enhanc-
ing strategies for improving the use of Artemisinin-based Combination Therapy 
(ACT). The study analyzed the demand and sales pattern of antimalarial drugs in 
private retail outlets to assess the current state of compliance to policy. Methods: 
A prospective cross-sectional survey of randomly selected drugs retail outlets in 
Enugu urban, south east Nigeria, was conducted between May and August, 2013, to 
determine the types, range, prices and sales pattern of antimalarial drugs as well 
as concomitant medications, from pharmacies and patent medicine outlets. Data 
was collected and analysed for antimalarial drugs demanded for and sold by self-
medication, treatment by retail outlets and prescription from hospitals. Results: 
With a total of 1,321 dispensed antimalarial drugs, ACTs accounted for 72.7% while 
monotherapy was 27.3%. AMFm drugs contributed 32.7% (n = 314) of ACTs. 46.5% 
(614) of the drugs were dispensed from self-treatment by patients. Treatment by the 
retail outlets accounted for 35.8% (n = 473) while 17.7% of the drugs were dispensed 
from hospital prescriptions. The median cost of the ACTs, at $3.23 is about three 
times the median cost of monotherapy ($0.97). Total cost of treatment, including 
concomitant medications averaged $3.34 (±$1.90). The AL brand was the most used 
ACT, at 69.3% (n = 666). Self-medication accounted for the highest number of mono-
therapy at 82% ConClusions: The use of ACTs as predominant antimalarial drugs 
of choice has become widespread in the retail outlets, with significant contribu-
tions from AMFm drugs. This portends positive implications on the implementation 
of antimalarial drugs policy. However costs of policy recommended drugs remain 
higher than intended and the use of monotherapy particularly through self-med-
ication is significant suggesting additional measures to directly target consumers 
for improved use of antimalarial drugs.
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objeCtives: To describe current utilization of HIV drugs in Canada. Methods: 
Longitudinal pharmacy retail data were obtained from most Canadian provinces. 
Eligible patients received their first HIV drug prescription during the selection 
period, and consistently filled subsequent prescriptions at the same pharmacy. 
Selection periods included an early cohort (initiating therapy January 2008 to 
July 2009) and a late cohort (initiating therapy August 2010 to February 2012). The 
observation period was 43 months for the early cohort and 12 months for the late 
cohort. Results: 905 patients in the early cohort and 1,411 patients in the late 
cohort were analysed. Single-tablet regimens were the initial therapy for 32% of 
patients (early cohort) and 33% (late cohort). The most commonly used regimen 
was a backbone + protease inhibitor (PI): 45% of total days on therapy (DOT) for early 
cohort, 39% for late. Darunavir was increasingly chosen as the initial PI (3% patients 
for early cohort, 16% for late). Backbone plus integrase inhibitor (II) increased from 
2% DOT (early cohort) to 11% in the late cohort. The majority of II patients were 
treatment-naïve (71%) in the late cohort, despite funding limitation to treatment-
experienced patients in most jurisdictions. After 3 years of follow-up in the early 
cohort, 45% were still on their first therapy. For early-cohort patients who switched 
to a second therapy, 33% did so within 3 months. Subsequent lines of therapy phased 
in more gradually in both cohorts. Darunavir and II use increased in later lines of 
therapy for both cohorts, but particularly for the late cohort. ConClusions: This 
research documented changing patterns for HIV drug use in Canada, with increasing 
use of darunavir and II over time (irrespective of funding restrictions) and frequent 
early therapy switches suggestive of tolerability issues.
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treatment effectiveness, recurrence rates, mortality rates, and costs. Results: In 
the general population 5% -20% of adults are estimated to be asymptomatic carri-
ers of CDI but up to 80% of the elderly in LTCF are colonized. Over 50% of cases are 
associated with hospitals and LTCFs. Growing number of cases have onset in the 
community. 9% of patients over 65 experience severe episodes compared to 4% for 
those below 65. Mortality rates for elderly are much higher. Patients over 65 experi-
ence almost twice the recurrence rate (38%), compared with younger populations 
(18% -22%). The rates for a second recurrence are 38% for those 65+ versus 24% 
below 65. The probability of recurrent CDI increases with the number of recurrences 
experienced. Recurrences were associated with major increases in hospital LOS and 
in costs. ConClusions: Our age-specific model allows to project and to quantify 
the impact of a CDI outbreak in terms of clinical burden and costs. Using a scenario-
based approach, comparisons of current treatments with the novel approach of 
duodenal infusion (fecal transplant) are carried out.
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bACkgRound: Children 6 months through 18 years of age are consistently identified 
as a high-risk population for influenza infections. Since 2007, the Advisory Committee 
on Immunization Practices (ACIP) emphasized children aged 6 months to < 9 years 
receive two doses of influenza vaccine in a season. Poor compliance with this two-
dose regimen has been described in recent years. However, since ACIPs two-dose 
recommendation in 2007, predictors of two-dose compliance have not been assessed 
using population-based data. objeCtives: This study analyzed data from influenza 
seasons 2008-2011 to examine two-dose compliance for children aged 19-35 months. 
This analysis tests for significant demographic and socioeconomic differences in one- 
and two-dose influenza vaccinations. Methods: Seasonal influenza vaccinations of 
children were estimated from the National Immunization Survey (NIS). The analysis 
results were nationally representative by weighting the study population according 
to survey weights and cluster variables. Primary outcome measures were at least one 
dose and two doses of influenza vaccination during September 1 through December 
31 of the season. For each season, the proportion of children with partial and full 
influenza vaccinations were calculated. Multivariate regressions modeled the effect 
of multiple NIS factors (i.e., age, race, gender) on influenza vaccination. Results: 
For all four seasons, adjusted one-dose influenza vaccination was significantly lower 
among children 24-35 months compared to children 19-23 months (ranging from 
7.8-44.5%, p< 0.05). Furthermore, one- and two-dose influenza vaccination was lowest 
among children living below the poverty level compared to children living above the 
poverty level (ranging from 9.4-53.7%, p< 0.05). ConClusions: Policies to improve 
one- and two-dose influenza vaccination rates should target children living below 
the poverty level. Efforts to improve one-dose vaccination rates among older infant 
children should continue. Further studies are needed to determine the reasons for 
initiating influenza vaccinations among children less than 24 months of age.
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objeCtives: This study aimed to evaluate if high antibiotic consumption is explained 
by inappropriate prescribing, given current practice guidelines. This is assessed 
through measuring the proportion of Upper Respiratory Tract Infection (URTI) treated 
by GPs with Co-amoxiclav, and Urinary Tract Infection (UTI) treated with fluoroqui-
nolones, comparing across population subgroups for differential treatment pat-
terns. Methods: This cohort study included records of all Clalit members visiting 
physicians from 4300 clinical practices during 2011. Rule-based algorithms were used 
to classify multiple primary care visits into discrete URTI and UTI events and link 
these with Ab prescriptions and dispensing. Infectious events and antibiotic prescrip-
tion rates were calculated. Differences in distributions across districts and population 
subgroups were then tested with Chi-square analysis; for prescribing ratios for UTI the 
ratio for prescribing fluoroquinolones vs. Nitrofurantoin (narrow-range Ab of choice) 
were calculated. Results: 6.5 million visits for infectious diagnoses were registered 
for all 4 million enrollees. Almost 75% of the Co-amixiclav dispensed was used for 
treatment of URTI, with 6% of URTI events treated with Co-amoxiclav. Over 75% of 
fluoroquinolones dispensed were used to treat UTI, with 23% of UTI events treated 
with fluoroquinolones. Variability between districts in the use of Co-amoxiclav for 
URTI ranged between 12%-23% in adults and 5%-21% in children. Twenty percent of 
physicians were co-amoxiclav “prescribers” with high rates of URTI events treated 
with co-amoxiclav (10%-38%). Treatment of UTI events with Quinolons varied con-
siderably between 19%-52%. The proportion of Quinolons\Nitrofurantoin prescribed 
ranged between 1.4 (1.3-1.5) to 6.2 (5.5-6.8) in each district. ConClusions: Rates 
of utilizing broad-spectrum antibiotics in the community are higher than expected 
and show wide variability across country districts and between physicians This sug-
gests the need for introducing this as a quality measure and implementing targeted 
interventions to reduce inappropriate antibiotic use.
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objeCtives: To evaluate efficacy, safety (concerning hypernatremia), and usage 
of UFO® in a medical center Methods: A retrospective medical record review 
was conducted for patients who is treated with UFO® in Wan-fang hospital during 
2012/5/1 to 7/8. Patients with cancers were excluded. Patients with suspected or 
diagnosed infections and more than one dose of UFO® were included. For hyper-
natremia analysis, only included patients with serum sodium level and no hyper-
natremia events prior UFO use. Microsoft excels and student t-test were utilized 
